论文部分内容阅读
目的:观察研究吉西他滨联合奥沙利铂(GEMOX)治疗晚期非小细胞肺癌的疗效和不良反应,并与吉西他滨联合顺铂(GP)方案相比较。方法:自2002年6月~2003年6月, 40例晚期非小细胞肺癌随机均分为GEMOX组(Gem1 000mg/m2,d1、d8;L OHP65mg/m2,d1、d8 )和GP组(Gem1 000mg/m2,d1、d8;DDP25mg/m2,d1 ~d3 )进行治疗,两方案均为3周重复。结果:GEMOX组和GP组的总有效率分别为55.0%和40.0%;两组的疾病进展时间(TTP)分别为33周和30周;差异均无显著意义。毒副作用方面,GP组3~4度白细胞减少、恶心呕吐和肾毒性明显高于GEMOX组。生活质量方面,无论QOL评分或PS评分,GEMOX组明显好于GP组。结论:吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌,疗效与GP方案相仿,毒副作用轻,治疗耐受性好,是较为理想的化疗方案。
OBJECTIVE: To observe the efficacy and adverse reactions of gemcitabine combined with oxaliplatin (GEMOX) in the treatment of advanced non-small cell lung cancer (NSCLC) and to compare with gemcitabine plus cisplatin (GP) regimen. Methods: From June 2002 to June 2003, 40 patients with advanced non-small cell lung cancer were randomly divided into GEMOX group (Gem1 000mg / m2, d1, d8; L OHP65mg / m2, d1, d8) and GP group 000mg / m2, d1, d8; DDP25mg / m2, d1 ~ d3) for treatment, the two programs were repeated for 3 weeks. Results: The total effective rates of GEMOX group and GP group were 55.0% and 40.0%, respectively. The time to progression of disease (TTP) in both groups were 33 weeks and 30 weeks respectively. There was no significant difference between the two groups. Toxic side effects, GP group 3 to 4 leukopenia, nausea and vomiting and nephrotoxicity was significantly higher than the GEMOX group. In terms of quality of life, GEMOX group was significantly better than GP group regardless of QOL score or PS score. Conclusion: Gemcitabine and oxaliplatin combined with oxaliplatin in the treatment of advanced non-small cell lung cancer have the same curative effect as GP regimen, light toxic side effects and good treatment tolerance. It is an ideal chemotherapy regimen.